The current study describes a statistically significant increase in macrophages (CD68-positive cells) in the decidua of preeclamptic patients. To elucidate the regulation of this monocyte infiltration, expression of monocyte chemoattractant protein-1 (MCP-1) was assessed in leukocyte-free first trimester decidual cells. Confluent decidual cells were primed for 7 days in either estradiol or estradiol plus medroxyprogesterone acetate to mimic the decidualizing steroidal medium of the luteal phase and early pregnancy. The medium was exchanged for a serum-free defined medium containing corresponding steroids +/- tumor necrosis factor (TNF)-α or interleukin (IL)-1β. After 24 hours, enzyme-linked immunosorbent assay measurements indicated that the addition of medroxyprogesterone acetate did not affect MCP-1 output, whereas 10 ng/ml of TNF-α or IL-1β increased output by 83.5-fold ± 20.6 and 103.1-fold ± 14.7, respectively (mean ± SEM, n = 8, P < 0.05). Concentration-response comparisons revealed that even 0.01 ng/ml of TNF-α or BL-1β elevated MCP-1 output by more than 15-fold. Western, blotting confirmed the enzyme-linked immunosorbent assay results, and quantitative reverse transcriptase-polymerase chain reaction confirmed corresponding effects on MCP-1 mRNA levels. The current study demonstrates that TNF-α and IL-1β enhance MCP-1 in first trimester decidua. This finding suggests a mechanism by which recruitment of excess macrophages to the decidua impairs endovascular trophoblast invasion, the primary placental defect of preeclampsia. Copyright © American Society for Investigative Pathology.
CITATION STYLE
Lockwood, C. J., Matta, P., Krikun, G., Koopman, L. A., Masch, R., Toti, P., … Schatz, F. (2006). Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor-α and interleukin-1β in first trimester human decidual cells: Implications for preeclampsia. American Journal of Pathology, 168(2), 445–452. https://doi.org/10.2353/ajpath.2006.050082
Mendeley helps you to discover research relevant for your work.